📈 69% of S&P 500 stocks beating the index - a historic record! Pick the best ones with AI.See top stocks

BRIEF-Raptor Pharma expands rare disease portfolio with acquisition of Quinsair

Published 2015-08-20, 05:24 p/m
© Reuters.  BRIEF-Raptor Pharma expands rare disease portfolio with acquisition of Quinsair
RPTP
-

Aug 20 (Reuters) - Raptor Pharmaceutical Corp RPTP.O :
* Expands rare disease portfolio with the acquisition of Quinsair(TM)
* Under the terms of the agreement, Raptor will pay $68.4 million upfront
* Says reiterating its 2015 revenue guidance of $80 to $90 million
* Raptor will have single-digit contingent obligations to two additional
parties involved in quinsair's development
* Says Raptor plans to launch quinsair in Europe and Canada in the first half
of 2016
* Says up to $34.2 million of closing consideration payable in Raptor common
stock at raptor's election
* Says co will pay contingent payments of up to $350 million associated with
development, regulatory,commercial milestones
* Raptor is acquiring exclusive global rights and assets to develop,
manufacture and commercialize quinsair
* Source text for Eikon ID:nGNXVEGZDa
* Further company coverage RPTP.O

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.